← All trials
NCT04276662
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 26, 2019
- Primary completion
- Dec 31, 2020
- Completion date
- Dec 31, 2020
- First posted
- Feb 19, 2020
- Last posted
- Feb 19, 2020
- Enrollment
- 28
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Daiichi SankyoLead sponsor
- Daiichi SankyoStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.